Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience
01 Pubblicazione su rivista
Marchetti C., Musella A., Romito A., Vertechy L., Palaia I., Di Donato V., Boccia S., De Felice F., Monti M., Muzii L., Benedetti Panici P.
DOI: 10.1159/000475668
ISSN: 0030-2414
The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens.